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Review article
Application of n-of-1 treatment trials in
schizophrenia: systematic review
Katie F. M. Marwick, Anna J. Stevenson, Caitlin Davies and Stephen M. Lawrie
Background
Single patient or ‘n-of-1’ trials are a pragmatic method to achieve
optimal, evidence-based treatments for individual patients. Such
trials could be particularly valuable in chronic, heterogeneous,
difficult to treat illnesses such as schizophrenia.
Aims
To identify how often, and in what way, n-of-1 trials have been
used in schizophrenia.
Method
We performed a systematic search in the major electronic
databases for studies adopting n-of-1 methodology in schizo-
phrenia, published in English from the start of records until the
end of January 2017.
Results
We identified six studies meeting inclusion criteria. There was
wide variability in study methodology and analysis. Each trial
reported positive outcomes for their respective intervention, but
all studies were at high risk of bias.
Conclusions
In conclusion, n-of-1 trials are currently underutilised in schizo-
phrenia. Existing trials suggest the method is well tolerated and
potentially effective in achieving optimal treatments for patients,
but more standardised methods of design, execution and ana-
lysis are required in future trials.
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Key concepts in n-of-1 trials
n-of-1 trials are arguably the future of evidence-based care in
schizophrenia. An n-of-1 trial is simply a prospective crossover
study of a single patient exposed to different treatment conditions.
For example, repetitively comparing a treatment (A) against no
treatment (B) (AB, BA) or comparing treatment A against no treat-
ment, against a second treatment C (AB, AC). n-of-1 trials are par-
ticularly useful for chronic conditions that are relatively stable over
time and where substantial clinical uncertainty exists over the best
treatment – such as choice of antipsychotic or other treatment selec-
tion in schizophrenia.
n-of-1 trials are very similar to normal ‘trial and error’ clinical
practice but with additional measures to reduce bias. Key measures
include: balanced treatment v. comparison sequence assignment
(which may be aided by randomisation if a large number of treat-
ment blocks are used), blinding (to the extent to which this is pos-
sible), and systematic outcome measurements.1 For psychotropic
medications where onset and cessation of effect are slow, building
in appropriate run-in and wash-out periods to the design is also
important.
Relevance to schizophrenia
n-of-1 trials have existed for decades yet are only now becoming
increasingly important in psychiatry and other branches of medi-
cine for three main reasons. First, the improved understanding of
the genetic determinants of disease means that personalised treat-
ment based on a patient’s particular genetic risk factors is now a
reality for some (for example in cancer2 and epilepsy3) and likely
to be available to all in years to come.4 Conceivably thousands of
individualised treatments may be indicated to treat highly penetrant
ultra-rare or de novo genetic variants associated with a large pro-
portion of severe intellectual disability,5 autism6 and, to a lesser
extent, schizophrenia.7 The discovery of auto-antibodies against
neurotransmitter receptors underlying a subset of psychotic disor-
ders that previously could have been diagnosed as schizophrenia
also emphasises that schizophrenia is not a homogeneous entity.8
The uncovering of the likely heterogeneity of mechanisms under-
lying psychiatric disorders such as schizophrenia means a robust
method of assessing response to treatment is required at the individ-
ual level, in addition to the group.
Second, n-of-1 trials are the epitome of patient-centred care.
They can be used to help those patients whom randomised con-
trolled trials fail: those with comorbid physical, mental or substance
use problems, those requiring concurrent medication and those at
the extremes of age. Many of these limitations of generalisability
apply in medication trials in schizophrenia. n-of-1 trials remove
the altruistic component of trial participation and give benefit
direct to the individual, which is particularly important for vulner-
able groups. Further, n-of-1 trials are easily adaptable to patient
preference in terms of interventions trialled and outcome measures
assessed. This is important because patient engagement improves
outcomes in chronic illness9 and participation in n-of-1 trials for
conditions such as attention-deficit hyperactivity disorder can
increase empowerment and feelings of control.10
Finally, n-of-1 trials are coming of age as technology to facilitate
the systematic assessment of health outcomes is increasingly
affordable and available. Regular assessment of predefinedmeasures
of response and harm is a key component of an n-of-1 trial.
Historically, this has been a resource-intensive process requiring
frequent clinician–participant interactions, but the availability of
smart phones and ancillary devices (able to record measures such
as heart rate, vocal stress and electroencephalograms) means that
regular assessment of both physiological and subjective parameters
is now much more readily available. Such technology has been har-
nessed by a recent n-of-1 trial series assessing the impact of statins
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on muscle pain11 and self-monitoring mobile phone applications
are already showing feasibility and benefit in mental health disor-
ders,12 including psychotic conditions.13
People with schizophrenia are therefore a key group who are
likely to benefit from n-of-1 trials. However, the number and
value of existing n-of-1 trials in this patient group is currently
unknown. We thus systematically reviewed the available literature
on n-of-1 trials in patients with schizophrenia to establish how com-
monly they are used, the approach to their application, the accept-
ability of the method to the patient group, and the strengths and
weaknesses of existing trials. Our findings aim to inform and
improve n-of-1 trials in schizophrenia in the future.
Method
Search strategy and selection criteria
We searched MEDLINE (Ovid interface, Ovid MEDLINE in-
process and other non-indexed citations and Ovid MEDLINE
1946 onwards), Embase (Ovid interface, 1980 onwards), Cochrane
Library (Wiley online platform), Web of Science (core collection)
and PsycINFO (Ovid interface 1987 to current) for relevant articles
indexed as of 2 February 2017. The following search terms were
used (“N-of-1” OR “single patient trial” OR (“individual” OR
“single” OR “within”) AND (“patient” or “participant” or
“subject”)) OR (“case stud*” AND “experiment”)) AND (“schizo-
phrenia” OR “Psychotic” OR “neuroleptic malignant syndrome”
OR “dyskinesia”), and their synonyms, as described in
Supplementary Appendix 1 available at https://doi.org/10.1192/
bjp.2018.70. Papers citing influential early ‘n-of-1’ publications14–16
were also screened for their own eligibility.
All titles and abstracts yielded by the searches were screened by A.
J.S., with a random sample of 10% screened byC.D. and discrepancies
resolved by discussion. The full texts were screened by A.J.S. We
included any peer-reviewed studies that exploited an n-of-1 study
designas a treatment trial for an individual patientwith schizophrenia.
We defined n-of-1 studies as those that adhered to the definition
described in the Consolidated Standards of Reporting Trials
(CONSORT) extension for reporting N-of-1 Trials (CENT) 2015 –
a single participant trial, using a repeated series of treatment challenge
and withdrawal, where one cycle (A) is the intervention being inves-
tigated and the other (B) is either a comparative treatment, a
control or no intervention.17 Studies that provided insufficient trial
detail or were not published in English were excluded.
Data were extracted independently by A.J.S. and K.F.M.M. Data
extracted from each study were: first author, year of publication,
country of study, duration of study, patient characteristics (age,
sex and diagnosis), trial design, intervention(s) used, comparator
used, blinding measures, primary outcome measures, method of
analysis, results and other outcomes. We adapted the CENT 2015
checklist17 to assess how well the studies were reported
(Supplementary Table 1). We also assessed the quality of studies
using the Cochrane risk of bias criteria, commonly used when asses-
sing clinical trials.18 See Supplementary Table 2 for the PRISMA
checklist for this review. We did not register a review protocol.
Ethics committee approval was not required.
Results
Study characteristics
We assessed 4727 citations, of which six studies met inclusion cri-
teria (Fig. 1). The included studies are summarised in Table 1.
Five studies reported on a single patient: three men and two
women. One study reported an n-of-1 series involving four
participants (two men and two women). All participants had
received a diagnosis of schizophrenia and were stabilised on anti-
psychotic medication. Patient ages ranged from 18 to 55 years
old, and each had a prolonged history of psychosis and psychiatric
intervention, ranging from 2 to 22 years. As expected, each patient’s
presenting problem, the rationale for employing an n-of-1 approach
and the discrete objectives for using each intervention differed
greatly between studies.
Study length ranged from 8 to 30 weeks, although one
study failed to report duration. Trial designs were diverse with
minimal replication: two of the studies adopted an ABAB crossover
design,19,20 two an ABA reversal design,21,22 one an ABAC design23
and one a BAB design.24 The nature of interventions trialled was
also wide ranging: two studies investigated pharmacological inter-
ventions (L-dopa21 and donepezil20), two a psychological interven-
tion (‘social reinforcement-assisted cognitive intervention’19 and
exercise counselling22), and two a physical intervention (ear plug
and transcranial magnetic stimulation). Comparison phases were
varied, comprising a mixture of placebos (inactive tablet,21 ear
plug in opposite ear,23 normal conversation19) and treatment as
usual.20,22,24
Two studies reported blinding measures, with one blinding both
the patient and the evaluating physician,21 and the other only
blinding the secondary outcome assessors.19 Of the other four
studies, one discloses that no blinding occurred20 and the others
fail to declare whether or not any measures of blinding were
applied.22–24
Outcome measures largely comprised assessments of psycho-
logical functioning; three papers used standardised assessments
and the other three tailored their outcome measures to the individ-
ual patient and intervention in question (Table 1). Four of the
studies employed both subjective and objective outcome mea-
sures.19–22 In one case the objective measure (frequency of exercise
via an accelerometer) showed no benefit from the intervention, in
contrast to some of the self-report measures.22 Frequency of collec-
tion of outcome measures varied considerably. The description of
results and analytical measures were largely underreported or
underemployed: three papers offered graphical and tabulated data
and a qualitative summary19,20,22 but did not report comprehensive
Studies identified from
search strategy: 4725
Studies after duplicates removed:
3729
Studies screened
(title and abstract):
3729
Full-text articles
assessed for
eligibility:
133
Full-text articles
excluded:
127
Studies included:
6
Studies excluded:
3596
Wrong study design: 80
Duplicate: 22
Not a primary study: 18
Wrong disorder: 4
Text not in English: 3
Additional studies identified
from other sources: 2
Fig. 1 Study selection.
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Table 1 Study characteristics with key patient data
Patient characteristics
Trial
design Duration Intervention used
Comparator
used Blinding Main outcome Measure(s) Analysis Main Result(s)
Alford
(1986)19
22-year-old man with chronic
paranoid schizophrenia (DSM III)
receiving fluphenazine
decanoate
ABAB Not reported Cognitive
intervention
(Social
reinforcement-
assisted)
Placebo (general
conversation)
Patient and treating
physician not
Blinded. Blinded
secondary outcome
assessors
Self-reports of frequency and
strength of delusional
belief, and frequency of
Thorazine (when required)
use
Qualitative
and
graphical
Decreasing frequency and
strength of belief in
delusion ideation
during treatment
phases. Decreased
administration of
Thorazine (when
required)
Blanco-
Lopez
et al
(2016)24
18-year-old woman with
schizophrenia receiving
clozapine
BAB 8 weeks Transcranial
magnetic
stimulation of left
temporoparietal
cortex
Treatment as
usual
None reported Unclear but appeared to be
self-report of duration of
time without auditory
hallucinations and
depressive symptoms.
Also clinical global
impression
Qualitative Decreasing frequency of
auditory hallucinations.
Improved mood.
Improved clinical
impression
Done et al
(1986)23
42-year-old man with chronic
schizophrenia receiving
flupentixol decanoate 150 mg
weekly. Target symptom
auditory hallucinations
ABAC 5 months Right ear plug No ear plug (B)
and left ear
plug only (C)
None reported Self-report of frequency,
volume and disturbing
content of hallucinations
Non-
parametric
statistics
Right ear plug reduced the
frequency and volume
of hallucinations
compared with left ear
plug or no plug
Gorczynski
et al
(2014)22
4 patients, all with chronic
schizophrenia: a 29-year-old
man receiving clozapine; a 28-
year-old man receiving
loxapine; a 25-year-old woman
receiving clozapine, and ‘weight
reduction medication’; a 36-
year-old woman receiving
clozapine
ABA 10 weeks Exercise counselling Treatment as
usual
None reported Self-report of stage of
change, self-efficacy and
benefits and barriers.
Objective assessment of
exercise via
accelerometer
Parametric
statistics,
graphical
and
tabular
No effect on objective
assessment of
exercise. Self-report
indicated progress
through stages of
change and minor
increases in self-
efficacy
Kay & Opler
(1985)21
55-year-old woman with chronic
paranoid schizophrenia (DSM III)
receiving haloperidol 15 mg
Reversal
design
(ABA)
27 weeks L-dopa (Sinemet)
(combined with
haloperidol)
Placebo
(combined
with
haloperidol)
Double-blind Brief Psychiatric Rating Scale,
Psychopathology Rating
Schedule, Span of
Attention Test
Non-
parametric
statistics
Significant improvement in
negative symptoms. No
change in positive
symptoms
MacEwan
et al
(2001)20
36-year-old man with
schizophrenia-paranoid type (in
partial remission) receiving
risperidone 2 mg
ABAB 30 weeks Donepezil (10 mg
daily)
Treatment as
usual
None Battery of 9 standardised
cognitive tests. Self-report
of functioning
Simple
tabulation
and
qualitative
summary
Increased verbal fluency
and subjective
concentration
System
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raw data scores. Statistical tests were employed by three studies but
lacked both full reporting of the tests and the raw data used.21–23
One study gave a selective sample of raw data only.24
Five of the studies had positive outcomes for the intervention
under investigation; two papers that reported statistical analysis
showed some statistically significant benefit of the experimental
treatment in question21,23 whereas the studies which described out-
comes qualitatively described a trend of improvement. The study
reporting on exercise counselling had mixed findings: it did not
find an objective benefit of the intervention but did find some
improvement in self-report measures.22 One paper reported that
their patient continued on the treatment that was being assessed20
and one study found that the outcome remained highly positive
several months later without any further intervention required.24
Two other studies reported qualified positive outcomes of follow-
up assessments19,23 but did not indicate if the treatment under
investigation was continued.
Quality assessment
Currently, there are no standardised measures for quality assess-
ment in n-of-1 trials so we assessed studies using a standard
measure of risk of bias often used in assessments of randomised
controlled trials18,25 (Table 2). Overall, the trials were assessed as
at high risk of bias, with reduced quality because of insufficient
reporting of trial detail, insufficient blinding and insufficient
numbers of replications of treatment pairs, without opportunity
for randomisation or counterbalancing. We also used the CENT
2015 checklist to provide a measure of the completeness and
clarity of the reporting of the included studies, which again high-
lighted gaps in reporting (see Supplementary Table 1).
Discussion
Main findings
The most prominent finding of this review is the paucity of n-of-1
trials in the current schizophrenia literature. We found only six
studies that corresponded to our inclusion criteria, indicating that
the increasing recognition of n-of-1 trials and declarations of inter-
est in personalised psychiatry has not yet translated to research in
schizophrenia. Comparison of the key study characteristics reveals
the variability in methodological and interventional approaches
adopted in such trials: we found one study investigating whether
or not an ear plug could reduce auditory hallucinations, one asses-
sing whether transcranial magnetic stimulation could reduce audi-
tory hallucinations, one testing if L-dopa could alleviate negative
symptoms, one assessing adjunctive use of donepezil, one using a
cognitive intervention to alter delusional beliefs and one assessing
the benefits of exercise counselling on activity. The studies encom-
passed the spectrum of psychiatric treatment modalities, which is
promising, indicating this form of trial is viable in the investigation
of the range of interventions that are often considered in the
complex management of schizophrenia and other psychiatric disor-
ders. None of the trials reported any adverse effects, or any issues
with patient adherence or acceptability, and they mainly reported
positive outcomes, suggesting that such trials are both feasible and
potentially valuable in patients with schizophrenia.
Risk of bias
The studies were, however, all considered to be at high risk of bias,
largely because of a lack of clarity and depth in their reporting and
because they did not include key design features such as blinding
and counterbalanced treatment conditions. Our results are similar
to comprehensive reviews looking at n-of-1 trials across the
medical literature, suggesting these issues need addressing through-
out medicine.26,27 All but one of the studies were published before
trial reporting guidelines,17 and the availability of these should
improve future n-of-1 trial reporting.
Blinding of the treatment provider and to a lesser extent the
patient will always be more difficult in studies providing non-
pharmacological interventions, whether the study is a randomised
control trial28 or an n-of-1 trial. However, blinding of outcome
assessors remains possible, and this also was lacking in the majority
of studies.
Additional areas that all of the studies here could have improved
on would have been to reduce the risk of bias because of natural
Table 2 Cochrane risk of bias table, modified for n-of-1 trials
Bias reduction
measure Application to n-of-1
Alford
(1986)19
Blanco-
Lopez et al
(2016)24
Done et al
(1986)23
Gorczynski
et al (2014)22
Kay &
Opler
(1985)21
MacEwan et al
(2001)20
Random sequence
generation
Counterbalancing more appropriate than
randomisation if small number of blocks
X X X X X X
Allocation
concealment
Less important than in randomised controlled
trial as crossover design: both treatments
will be received over time
X X X X X X
Blinding
(participants
and personnel)
May be harder in small-scale, naturalistic trials.
May be less relevant as non-specific effects
still worthwhile
X X X X ✓ X
Blinding (outcome
assessors)
Particularly difficult if patient is collecting data
on themselves
? X X X ✓ X
Completeness of
outcome data
for n-of-1 trials, participant drop-out not
relevant, but missing data for main
outcomes still relevant
X X X ? X X
All outcomes
reported
X ? X ✓ X X
Other sources of
bias minimised
for n-of-1 trials, key source of bias is carry-over
of treatments and variation of outcome by
time independently of treatment. This can
be minimised by counterbalanced
treatment orders and by multiple blocks
(replication)
X X X X X X
X, high risk; ?, unclear risk; ✓, low risk.
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variation over time by having more replication cycles (the largest
number of cycles was two) and by counterbalancing the treatment
and comparison arms (e.g. AB, BA rather than AB, AB). Longer
trial durations would also have reduced the risk of measuring
placebo and Hawthorne (halo) effects (change in behaviour
simply because of the attention received through being a research
participant).29 However, one trial found complete resolution of
symptoms following the second round of treatment, suggesting
that further treatment cycles would be a waste of resource and
even potentially harmful. Further, psychological interventions by
their nature are designed to have effects with duration beyond the
period of treatment, limiting the potential for multiple within-
patient replications. The diversity of even the small number of n-
of-1 trials considered here highlights the difficulty in dictating
quality standards that balance rigour with feasibility.
Use of patient-reported outcomes
Another challenge for future n-of-1 trials is to harness the potential
power of patients reporting their own outcomes (e.g. via smart
phones) while also ensuring objective assessments. Of the four
studies that reported both subjective and objective measures, the
findings conflicted in one. Overreliance on subjective assessment
can occur in group trials as well as n-of-1 trials, but n-of-1 trials
are made particularly vulnerable by their highly patient-centred,
sometimes bespoke and often low-resource nature. Patient satisfac-
tion with an intervention is important, but it is not the same as
effectiveness.
Limitations
We designed a comprehensive search strategy to ensure we captured
all examples of n-of-1 treatment trials in patients with schizophre-
nia that conformed to our definition; however, it is possible we over-
looked some relevant examples. One reason for this, and an area of
n-of-1 trials that needs work, is the lack of consensus in the nomen-
clature; there is no widely accepted, single definition of what consti-
tutes an n-of-1 methodology, with various opinions on a number of
fundamental aspects including the necessity for blinding and ran-
domisation and the requisite number of treatment cycles.1,30 This
variation reflects the adaptability and diversity of n-of-1 method-
ology, with different approaches and durations required for trials
using pharmacological v. psychological interventions, interventions
with a substantial v. a subtle impact, conditions with rapid v. slow
symptom responses and medications with short v. long speeds of
onset and discontinuation.
Furthermore, none of the papers included in this review expli-
citly identify themselves as an n-of-1 trial; instead they designate
themselves as ‘a single-subject experimental study’ (two studies),
‘a single-case experimental analysis’, a ‘single patient study’ and
‘an experimental design case study’, so although they do conform
to the CENT 2015 definition of n-of-1 trials this is perhaps more
by accident than by design. This means it can be challenging to
pick out such studies in the literature. We will also have missed
any studies published in a language other than English, and any
non-peer-reviewed studies in the ‘grey literature’.
It is also highly probable that not all n-of-1 trials that are exe-
cuted are published because of a lack of awareness of their potential
broader clinical value as, by design, they result in findings that defy
simple generalisation, meaning motivation to publish results may
not be high. This is particularly likely to be the case with negative
findings, potentially placing n-of-1 trials at higher risk of publica-
tion bias than trial designs in which pre-registration is the expect-
ation. Although the purpose of n-of-1 trials is to objectively
determine the optimal intervention for an individual using data-
driven criteria, generalisability and population-level clinical value
can be achieved by combining data from series of comparable
n-of-1 trials using meta-analytic statistical approaches, predomin-
antly Bayesian.31,32 Similar statistical approaches have also been
developed to interpret data from related trial methodologies such
as sequential multiple assignment randomised trials (SMART)33
(e.g. the CATIE study34), which could be viewed as n-of-1 trials
with a predefined sequence of treatment options and decision
points, and individual participant data meta-analysis.35 n-of-1
trials therefore represent a method flexible enough for individual
treatment optimisation that could also be standardised for wider
research into subsets of the population. Awareness of this value
should encourage their use, and may reassure pharmaceutical
companies and regulatory bodies that n-of-1 trials can provide evi-
dence strong enough to support marketing and licensing decisions
for specific groups.
Future directions
Despite the many potential benefits of n-of-1 trials, there has not yet
been a rise in such studies in the field of schizophrenia. Our review
suggests this is not because of a lack of feasibility or utility but
perhaps a lack of awareness of their value and the availability of a
formalised approach to their design and conduct. Resources are
now available for researchers to effectively plan, execute and
analyse such trials, allowing them to attain valuable results for
their patients, and potentially the wider population of those with
a diagnosis of schizophrenia. We hope that the next decade will
see a blossoming of high quality n-of-1 trials of various therapeutic
strategies in the management of schizophrenia and related
conditions.
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